<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217136</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-035</org_study_id>
    <secondary_id>2016-004820-41</secondary_id>
    <nct_id>NCT03217136</nct_id>
  </id_info>
  <brief_title>MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)</brief_title>
  <official_title>A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam)
      plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">September 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to Day 42</time_frame>
    <description>Number of participants with one or more AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuations</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Number of participants who discontinued study drug due to an AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response of cure</measure>
    <time_frame>Up to Test of Cure Visit (up to 28 days)</time_frame>
    <description>Percentage of participants who have a clinical response of cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological eradication of all baseline pathogens</measure>
    <time_frame>Up to Test of Cure Visit (up to 28 days)</time_frame>
    <description>Percentage of participants who have microbiological eradication or presumed eradication of all baseline pathogens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Complicated Intra-Abdominal Infection</condition>
  <arm_group>
    <arm_group_label>Ceftolozane/Tazobactam + Metronidazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum ceftolozane 1 g/dose and tazobactam 0.5 g/dose); plus Metronidazole 10 mg/kg (maximum 1.5 g/day) administered intravenously (IV) every 8 to 12 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem + Placebo for Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meropenem 20 mg/kg (maximum 1 g/dose) plus placebo for Metronidazole administered IV every 8 hours. After receiving at least 9 doses of IV study treatment, participants may be switched to open-label, standard-of-care oral step-down antibiotic therapy at the investigator's discretion. Total antibiotic duration (IV only or IV + oral) is a minimum of 5 days and a maximum of 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane</intervention_name>
    <description>Ceftolozane 20 mg/kg (maximum 1 g) administered IV every 8 hours for between 5 to 14 day</description>
    <arm_group_label>Ceftolozane/Tazobactam + Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazobactam</intervention_name>
    <description>Tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days</description>
    <arm_group_label>Ceftolozane/Tazobactam + Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants =&lt; 28 days old, start with a loading dose of 15 mg/kg; then if =&lt; 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if &gt; 2 kg are dosed 10 mg/kg every 8 hours.</description>
    <arm_group_label>Ceftolozane/Tazobactam + Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days</description>
    <arm_group_label>Meropenem + Placebo for Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Metronidazole</intervention_name>
    <description>Placebo for Metronidazole administered IV every 8 hours for between 5 to 14 days.</description>
    <arm_group_label>Meropenem + Placebo for Metronidazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a legal representative who provides written informed consent on the participant's
             behalf and provides age-appropriate written informed assent (as applicable) for the
             trial.

          -  Aged from birth (defined as &gt;32 weeks gestational age and ≥7 days postnatal) to &lt;18
             years of age.

          -  Require IV antibacterial therapy for the treatment of presumed or documented cIAI.

          -  Has an operative procedure for the current diagnosis and management of cIAI planned or
             completed within 24 hours of the first dose of an antibacterial drug.

          -  Has in compliance baseline intra-abdominal specimen collection.

          -  Is not of reproductive potential; but if of reproductive potential agrees to avoid
             becoming pregnant or impregnating a partner during screening, while receiving study
             treatment and for at least 30 days after the last dose of study treatment.

          -  Female of reproductive potential is not pregnant, and not planning to become pregnant
             within 30 days of the last day of treatment administration; and is nonlactating.

        Exclusion Criteria:

          -  Is currently participating in or has participated in an interventional clinical trial
             with an investigational compound or device within 30 days prior to the first dose of
             study treatment in this current trial.

          -  Has previously participated in any trial of ceftolozane or ceftolozane/tazobactam or
             has enrolled previously in the current trial and been discontinued.

          -  Has a history of any moderate or severe hypersensitivity (eg, anaphylaxis), allergic
             reaction, or other contraindication to any of the following: β-lactam antibiotics (eg,
             penicillins, cephalosporins, and carbapenems), β-lactamase inhibitors (eg, tazobactam,
             sulbactam, clavulanic acid, avibactam), or metronidazole.

          -  Has an IAI within the past 1 year prior to randomization known to be caused by a
             pathogen resistant to either IV study treatment.

          -  Has a concomitant infection at the time of randomization that requires nonstudy
             systemic antibacterial therapy in addition to IV study treatment or oral step-down
             therapy.

          -  Has received potentially therapeutic antibacterial therapy for a duration more than 24
             hours during the 48 hours preceding the first dose of study treatment, unless is
             considered to be failing antibiotic therapy for cIAI.

          -  Has any of the following: a) intractable cIAI that the investigator anticipates would
             require more than 14 days of study treatment; b) abdominal wall abscess; c) small
             bowel obstruction; d) ischemic bowel disease without perforation; e) traumatic bowel
             perforation with surgery within 12 hours of perforation; f) perforation of
             gastroduodenal ulcers requiring surgery within 24 hours of perforation; g) suspected
             uncomplicated intra-abdominal infection (eg, cholecystitis without rupture or
             extension beyond the gallbladder wall); h) acute suppurative cholangitis; i) infected
             necrotizing pancreatitis; j) pancreatic abscess.

          -  Has severe impairment of renal function.

          -  Has a seizure disorder or is anticipated to be treated with divalproex sodium or
             valproic acid during the course of study treatment.

          -  Is receiving, or is expected to receive, any prohibited medications.

          -  Has any rapidly progressing disease or immediately life-threatening illness, including
             acute hepatic failure, respiratory failure, or septic shock.

          -  Has an immunocompromising condition.

          -  Has a history of malignancy ≤5 years prior to signing informed consent.

          -  Is planning to receive suppressive/prophylactic antibiotics with gram-negative
             activity after completion of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital - Los Angeles ( Site 2508)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-361-5047</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County ( Site 2502)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-509-4791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center-Floating Hospital for Children ( Site 2516)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-636-5025</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital ( Site 2511)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-5128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital ( Site 2509)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>315-464-7353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital ( Site 2500)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>801-587-0694</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital ( Site 2510)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-884-5086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 0801)</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3652255603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kaunas ( Site 1001)</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37068744843</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klaipedos Vaiku Ligonine ( Site 1000)</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37068698725</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vaiku Ligonine VU ligonines Santariskiu kliniku filialas ( Site 1002)</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37068722516</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sefako Makgatho Health Sciences University ( Site 1901)</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27125215633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Deu ( Site 2000)</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34936009733</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago ( Site 2001)</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34981950615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe ( Site 2003)</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961244995</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova Uni Tip Fak Cocuk Saglıgı ve Hasta ABD ( Site 2200)</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905326534166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2201)</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324135130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi Unv. Tip Fakultesi ( Site 2202)</name>
      <address>
        <city>Eskisehir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905422423608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sisli Hamide Etfal Egitim ve Arastirma Hastanesi ( Site 2203)</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905055803297</phone>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

